PepGen's (PEPG) Buy Rating Reiterated at HC Wainwright

HC Wainwright reiterated their buy rating on shares of PepGen (NASDAQ:PEPG - Free Report) in a research report report published on Monday,Benzinga reports. They currently have a $16.00 price target on the stock. HC Wainwright also issued estimates for PepGen's Q1 2025 earnings at ($0.75) EPS, Q2 2025 earnings at ($0.74) EPS, Q3 2025 earnings at ($0.74) EPS, Q4 2025 earnings at ($0.74) EPS, FY2025 earnings at ($2.96) EPS, FY2026 earnings at ($2.54) EPS, FY2027 earnings at ($1.99) EPS, FY2028 earnings at ($1.26) EPS and FY2029 earnings at ($0.31) EPS.

Other equities research analysts also recently issued reports about the stock. Wedbush reduced their price target on shares of PepGen from $19.00 to $12.00 and set an "outperform" rating on the stock in a research note on Friday, November 8th. Bank of America downgraded shares of PepGen from a "neutral" rating to an "underperform" rating and set a $3.00 price target on the stock. in a research note on Monday, December 16th.

PepGen Stock Performance

Shares of PepGen stock traded up $0.90 on Monday, reaching $2.43. The company had a trading volume of 25,898,472 shares, compared to its average volume of 4,004,496. The firm's 50 day moving average price is $2.38 and its two-hundred day moving average price is $5.72. The firm has a market cap of $79.21 million, a PE ratio of -0.82 and a beta of 1.53. PepGen has a 52-week low of $1.16 and a 52-week high of $19.30.

Remove Ads

PepGen (NASDAQ:PEPG - Get Free Report) last released its quarterly earnings results on Monday, February 24th. The company reported ($0.68) earnings per share (EPS) for the quarter, beating analysts' consensus estimates of ($0.81) by $0.13. As a group, sell-side analysts predict that PepGen will post -2.73 EPS for the current year.

Institutional Investors Weigh In On PepGen

Large investors have recently added to or reduced their stakes in the business. China Universal Asset Management Co. Ltd. purchased a new stake in PepGen during the 4th quarter worth approximately $26,000. Allspring Global Investments Holdings LLC purchased a new stake in PepGen during the 3rd quarter worth approximately $95,000. XTX Topco Ltd purchased a new stake in shares of PepGen in the 3rd quarter valued at approximately $130,000. Corton Capital Inc. purchased a new stake in shares of PepGen in the 4th quarter valued at approximately $68,000. Finally, Barclays PLC increased its position in shares of PepGen by 318.7% in the 3rd quarter. Barclays PLC now owns 21,971 shares of the company's stock valued at $189,000 after purchasing an additional 16,723 shares during the last quarter. 58.01% of the stock is owned by hedge funds and other institutional investors.

About PepGen

PepGen Inc, a clinical-stage biotechnology company, focuses on the development of oligonucleotide therapeutics for use in the treatment of severe neuromuscular and neurologic diseases. Its lead product candidate is PGN-EDO51, an EDO peptide that is in Phase 2 clinical trial to treat Duchenne muscular dystrophy (DMD) patients.